Dapagliflozin in combination therapy for treating type 2 diabetes

Review proposal consultation

Stakeholder matrix (PDF 98 KB)

Review proposal paper (PDF 213 KB)

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping (PDF 32 KB)

Diabetes (type 2) - dapagliflozin: final appraisal determination information

Diabetes (type 2) - dapagliflozin: final appraisal determination document (PDF 480 KB)

Diabetes (type 2) - dapagliflozin: evaluation report information

Diabetes (type 2) - dapagliflozin: evaluation report (PDF 4.49 MB)

Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form (PDF 51 KB)

Diabetes (type 2) - dapagliflozin: appraisal consultation

Diabetes (type 2) - dapagliflozin: appraisal consultation document information

Diabetes (type 2) - dapagliflozin: evaluation report

Diabetes (type 2) - dapagliflozin: pre-briefing meeting (PDF 749 KB)

Diabetes (type 2) - dapagliflozin: Evidence Review Group report

Diabetes (type 2) - dapagliflozin: Evidence Review Group report (PDF 1.35 MB)

Diabetes (type 2) - dapagliflozin: changes to the ERG report (PDF 281 KB)

Diabetes (type 2) - dapagliflozin: Decision Support Unit report (PDF 875 KB)

Diabetes (type 2) - dapagliflozin: Evidence Review Group report - factual accuracy check (PDF 117 KB)

Diabetes (type 2) - dapagliflozin: ERG BMI analyses (PDF 105 KB)

Diabetes (type 2) - dapagliflozin: manufacturer submission

Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca (PDF 5.56 MB)

Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca addendum (PDF 741 KB)

Diabetes (type 2) - dapagliflozin: clarification

Diabetes (type 2) - dapagliflozin: NICE clarification letter (PDF 102 KB)

Diabetes (type 2) - dapagliflozin: Manufacturer response to the NICE clarification letter (PDF 959 KB)

Diabetes (type 2) - dapagliflozin: ERG's additional clarification questions and manufacturer responses (PDF 440 KB)

Diabetes (type 2) - dapagliflozin: patient group, professional group and NHS organisation submission statements

Diabetes (type 2) - dapagliflozin: Royal College of Nursing (PDF 11 KB)

Diabetes (type 2) - dapagliflozin: Royal College of Pathologists (PDF 51 KB)

Diabetes (type 2) - dapagliflozin: NHS  Middlesbrough (PDF 57 KB)

Diabetes (type 2) - dapagliflozin: expert written personal statements

Diabetes (type 2) - dapagliflozin: Kilpatrick Appendix D - clinical specialist statement (PDF 33 KB)

Diabetes (type 2) - dapagliflozin: Kuti Appendix K - patient/carer expert statement (PDF 214 KB)

Diabetes (type 2) - dapagliflozin: Linton - Appendix K NHS-Commissioning expert statement declaration (PDF 29 KB)

Diabetes (type 2) - dapagliflozin: Moulton - Appendix K - Patient/carer expert statement (PDF 106 KB)

Diabetes (type 2) - dapagliflozin: Ononeze - Appendix K NHS-Commissioning expert statement declaration (PDF 8.6 KB)

Diabetes (type 2) - dapagliflozin: Winocour - Appendix D clinical specialist statement (PDF 81 KB)

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping (PDF 32 KB)

Diabetes (type 2) - dapagliflozin: appendix B - final scope (PDF 67 KB)

Diabetes (type 2) - dapagliflozin: appendix C - final matrix (PDF 33 KB)

Diabetes (type 2) - dapagliflozin: appendix D - comments table (PDF 227 KB)

Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012 (PDF 78 KB)

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012 (PDF 39 KB)

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011 (PDF 68 KB)

Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011 (PDF 36 KB)